Fortrea (FTRE) – Investment Analysts’ Recent Ratings Changes

A number of research firms have changed their ratings and price targets for Fortrea (NASDAQ: FTRE):

• 3/4/2025 – Fortrea had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $22.00 to $11.00. They now have a “neutral” rating on the stock.
• 3/4/2025 – Fortrea had its “market perform” rating reaffirmed by analysts at William Blair.
• 3/4/2025 – Fortrea had its price target lowered by analysts at Evercore ISI from $20.00 to $15.00. They now have an “in-line” rating on the stock.
• 3/4/2025 – Fortrea had its price target lowered by analysts at Barclays PLC from $25.00 to $12.00. They now have an “equal weight” rating on the stock.

Fortrea Trading Down 0.1 %

Shares of FTRE stock traded down $0.02 during trading hours on Friday, hitting $10.68. The company had a trading volume of 1,380,197 shares, compared to its average volume of 1,461,433. Fortrea Holdings Inc. has a fifty-two week low of $9.55 and a fifty-two week high of $41.02. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.18 and a quick ratio of 1.18. The company’s fifty day moving average is $16.33 and its 200 day moving average is $18.89. The stock has a market capitalization of $957.55 million, a PE ratio of -3.12, a price-to-earnings-growth ratio of 1.78 and a beta of 1.34.

Fortrea (NASDAQ:FTRE) last released its quarterly earnings results on Monday, March 3rd. The company reported $0.18 EPS for the quarter, missing analysts’ consensus estimates of $0.36 by ($0.18). The firm had revenue of $697.00 million for the quarter, compared to analyst estimates of $703.22 million. Fortrea had a positive return on equity of 2.00% and a negative net margin of 10.99%. During the same quarter last year, the company earned $0.19 earnings per share. Research analysts expect that Fortrea Holdings Inc. will post 0.51 earnings per share for the current fiscal year.

Insider Activity at Fortrea

In other Fortrea news, CEO Thomas Pike sold 11,268 shares of the firm’s stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $18.04, for a total value of $203,274.72. Following the completion of the transaction, the chief executive officer now owns 159,868 shares of the company’s stock, valued at $2,884,018.72. This trade represents a 6.58 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Over the last quarter, insiders sold 12,386 shares of company stock worth $219,751. Corporate insiders own 0.12% of the company’s stock.

Institutional Investors Weigh In On Fortrea

Several large investors have recently bought and sold shares of FTRE. US Bancorp DE grew its position in shares of Fortrea by 97.5% during the third quarter. US Bancorp DE now owns 12,960 shares of the company’s stock worth $259,000 after buying an additional 6,398 shares in the last quarter. Hara Capital LLC purchased a new stake in shares of Fortrea in the 3rd quarter valued at approximately $29,000. Assetmark Inc. raised its holdings in shares of Fortrea by 10.7% in the 3rd quarter. Assetmark Inc. now owns 16,238 shares of the company’s stock valued at $325,000 after purchasing an additional 1,566 shares in the last quarter. Covestor Ltd raised its holdings in shares of Fortrea by 102.4% in the 3rd quarter. Covestor Ltd now owns 2,763 shares of the company’s stock valued at $55,000 after purchasing an additional 1,398 shares in the last quarter. Finally, Diamond Hill Capital Management Inc. lifted its position in shares of Fortrea by 20.5% during the 3rd quarter. Diamond Hill Capital Management Inc. now owns 1,197,696 shares of the company’s stock worth $23,954,000 after purchasing an additional 204,021 shares during the last quarter.

Fortrea Holdings Inc, a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum.